🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Chronic #hypoparathyroidism is associated with low bone turnover & abnormally dense bone structure but new study finds 35% of postmenopausal women have #osteoporosis and recommends skeletal monitoring in postmenopausal women and men over 50 with hypopara link.springer.com/article/10.100…

Sallee Hobbs, founder and leader of the rare disease charity Hypoparathyroidism New Zealand (Hypopara NZ) shares her rallying cry to help “crank up the volume” on the story of many living with a rare disease in New Zealand. rarerevolutionmagazine.com/were-not-here-…

Jessica shares her inspiring journey of living with autosomal dominant hypocalcemia type 1 (ADH1), a common genetic form of hypoparathyroidism. Explore her experience and discover the challenges and triumphs she faces along the way. Learn more about Jessica’s story here:

🔥 FEBRILE STUFF🔥 Basic Clinicals Wednesday 👨🏾‍⚕🧑🏾‍⚕🩺 PSEUDOHYPOPARATHYROIDISM 🎯 A very rare inborn error presenting with features of hypoparathyroidism 🎯 It is due to an impaired response of both kidneys and bone to parathyroid hormone

Quality of life in patients with permanent hypoparathyroidism after thyroidectomy for benign thyroid disease: population-based study with long-term follow-up ➡️doi.org/10.1093/bjsope… This population-based study aimed to provide a comprehensive understanding of the effects of

Such a full house on the presentation of the new European Society of Endocrinology (ESE) Guidelunes on chronic hypoparathyroidism, one has to follow from a screen outside the Hall 😎Still, great presentation of management including novel aspects of PTH replacement therapy!

At this year’s Pediatric Endocrine Society Annual Meeting, we are thrilled to share insight into the planned pediatric study design for autosomal dominant hypocalcemia type 1 (ADH1). Learn more about the genetic form of hypoparathyroidism here: bridgebio.com/what-is-adh1/

New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism - Check the Link for More shorturl.at/RXViX AscendisPharma #PTH #Rare_Diseases #Hypoparathyroidism #Orphan_Drugs #Drug_Development #ESPE

This week, Richard DiMarchi, Ph.D., Indiana University Prof., MBX co-founder & will present on the discovery process for our novel investigational parathyroid hormone replacement therapy at the 2nd Annual Hypoparathyroidism Summit. endocrine.org/-/media/endocr…